1000mg of (Hesperidin and Diosmin mixture) three times daily for 7 days 1000mg of (Hesperidin and Diosmin mixture) two times daily for 3 days

standard care therapy in quarantine hospitals

Coronavirus Infection

Hesperidin and Diosmin mixture

Hesperidin and Diosmin for Treatment of COVID-19

Randomized Double-blind Controlled Parallel Study of (Hesperidin and Diosmin Mixture) for Treatment of COVID-19 Newly Diagnosed Patients in Egypt

Prof. Dr. Kamal Mohammed Okasha

Professor

Tanta University

Randomized double-blind controlled Parallel study

Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks.

Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.

Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks.

Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.

Tinea

Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin

Isotretinoin

Terbinafine

Itraconazole 200 mg

Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis

A Pilot Study to Assess The Therapeutic Effectiveness Of Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis

The total number of patients who recur in the 4 different groups (comparing the paticipants who are on low dose isotretinoin during the follow up versus those who are not)

Dr. Tarun Narang

ASSISTANT PROFESSOR

Postgraduate Institute of Medical Education and Research

The investigators plan to include 15 patients with insect venom allergy and will collect blood at four time points and stool at three time points during the first week of immunotherapy.
The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients.

The investigators plan to include 15 patients with pollen allergy and will collect blood at five time points and stool at three time points during the first three months of immunotherapy.
The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients.

The investigators plan to include 10 control persons without a clinical history of allergies. Blood and stool samples will be collected at seven/four times respectively.
The patients will receive usual standard of care and no intervention.

Both lymphocytes and stool samples of the patients will be retained.

Allergy

Blood will be drawn by certified personnel according to local regulations. Stool will be collected by the patients after instructions on how to use a stool collection kit.

Blood draw, stool collection.

Centre Hospitalier de Luxembourg

Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy

Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy: Predicting the T Cell Activation Potential in Vivo From Resting T Cells of Patients

This study will allow to predict the T cell activation potential (by evaluating gene expression networks) in vivo before start of immunotherapy for insect venom or pollen allergy meaning that the investigators will be able to predict which patients will profit from standard immunotherapy and which patients will need to receive altered immunotherapy strategies (i.e. higher doses, longer maintenance).
As this is an observational pilot study the investigators define this as outcome measure.

Sebastian Bode, MD

Clinician Scientist

Luxembourg Institute of Health

Integrated Biobank of Luxembourg

Centre Hospitalier du Luxembourg

10 units of Botox intradermally injected into one forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.

Saline vehicle intradermally injected into the other forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.

10 units of both Botox and a saline vehicle will be intradermally injected into one forearm or the other on the first study visit. The subject will be blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
Botox: 10 units of Botox will be intradermally injected into one 4x4cm area on the volar forearm on 1st study visit.
Saline: 10 units of the Saline vehicle will be intradermally injected into one 4x4cm area on the contralateral volar forearm on the 1st study visit.

Botox and Saline Vehicle Control

Sex: Female, Male

Region of Enrollment

The primary endpoint is to test the antipruritic effect of Botox using an itch visual analog scale (VAS) intensity scale as an outcome measure. The itch VAS intensity scale ranges from a minimum of 0 (no itch - best) to a maximum of 10 (maximum itch - worst). Participants will rate itch intensity after itch is induced with cowhage.

10 units of Botox intradermally injected into one forearm

Botox

Saline vehicle intradermally injected into the other forearm

Saline

Itch by VAS Itch Intensity at Baseline (Visit 1)

Itch by VAS Itch Intensity at 1 Week (Visit 2)

Itch by VAS Itch Intensity at 1 Month (Visit 3)

Itch by VAS Itch Intensity at 3 Months (Visit 4)

A secondary endpoint is to see if Botox has a relieving effect on heat pain using a pain visual analog scale (VAS) intensity scale as an outcome measure. The pain VAS intensity scale ranges from a minimum of 0 (no pain - best) to a maximum of 10 (maximum pain - worst). Participants will rate pain intensity after pain is induced with a heat thermode.

Change in Heat Pain Relief by VAS Pain Intensity Reporting After 1 Week, 1 Month, and 3 Months After Treatment

Overall Study

Susan G. Fisher, M.S., Ph.D., Associate Dean and Director, Temple Clinical Research Institute

Pruritus

10 units of Botox will be intradermally injected into one 4x4cm area on the volar forearm on 1st study visit.

10 units of the Saline vehicle will be intradermally injected into one 4x4cm area on the contralateral volar forearm on the 1st study visit.

rhinitis/protease

Hesperidin and Diosmin for Treatment of COVID-19

Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis

Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy

Itch Relieving Effect of Botox: a Study in Healthy Subjects

Nasal Mucus Proteome and Immunotherapy

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus